Vaccine News and Research

Latest Vaccine News and Research

Polio vaccination campaign targeting 72M children in 15 African countries announced; Ugandan health authorities declare polio outbreak

The WHO on Tuesday announced a mass polio immunization campaign in 15 African countries targeting a total of 72 million children, Agence France-Presse reports. "Polio has spread again in recent years with cases imported from some of the four endemic nations in Asia and Africa, mainly Nigeria, in a setback to global attempts to eradicate the crippling and sometimes lethal disease," the news service writes (10/26).

28 Oct 2010

New findings suggest way to treat lung diseases

A new study of an exotic, infectious virus that has caused three recent outbreaks in the United States reveals clues to how the virus might damage lungs during infection. The findings also suggest possible new ways to treat lung diseases in humans.

28 Oct 2010

Flu deaths analyzed for future lessons

A new report has looked at all of England’s swine flu deaths in children under 18 during the 2009 pandemic. Researchers found that there was a higher risk of dying from the influenza A H1N1 strain of flu among certain groups of children, such as those with pre-existing conditions and those of a Pakistani or Bangladeshi background. However it was unclear why.

27 Oct 2010

Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium

Vical Incorporated today announced that the company's Vice President of Clinical Development, Richard T. Kenney, M.D., is presenting preclinical results from the company's herpes simplex type 2 (HSV-2) vaccine program in a poster session Friday morning at the Keystone Symposium on Immunological Mechanisms of Vaccination (Seattle, October 27 – November 1).

27 Oct 2010

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained an initial draft report of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON (OX1).

27 Oct 2010

Scripps Florida scientist receives grant from Landenberger Foundation for HIV research

A scientist on the Florida campus of The Scripps Research Institute has received funding from the Philadelphia-based Margaret Q. Landenberger Research Foundation.

27 Oct 2010

B.C. pharmacists are authorized to administer flu shots

As British Columbians get ready for flu season, the BC Pharmacy Association is reminding patients that they can get their seasonal vaccination from their pharmacist.

27 Oct 2010

USAID announces LAUNCH: Health innovators

The U.S. Agency for International Development (USAID), NASA, NIKE, Inc. and the U.S. Department of State are pleased to announce those selected to participate in the LAUNCH: Health Forum. The innovators selected will participate in an event at NASA's Kennedy Space Center in Florida October 30-31, followed immediately by the launch of the Space Shuttle Discovery on November 1.

27 Oct 2010

Older adults with severe sepsis at higher risk for cognitive impairment

Older adults who survive severe sepsis are at higher risk for long-term cognitive impairment and physical limitations than those hospitalized for other reasons, according to researchers from the University of Michigan Health System.

27 Oct 2010

Bivalent oral polio vaccine produces better immune response than more commonly used trivalent vaccine, study says

The bivalent oral polio vaccine (bOPV) was found to induce a significantly higher immune response than the existing trivalent oral polio vaccine (tOPV), according to a study published on Tuesday in the journal Lancet, Reuters reports.

27 Oct 2010

PPD and VirtualScopics partner to provide medical imaging services

PPD, Inc. and VirtualScopics, Inc. today announced a strategic alliance to deliver a comprehensive set of clinical and medical imaging services that will enable biopharmaceutical companies to make faster, more confident decisions on the development of their oncology compounds, creating time and cost efficiencies.

26 Oct 2010

72 million children to be immunized against polio across 15 African countries

This week, Africa seizes an unprecedented chance to drive out polio when 15 countries across the continent launch a synchronized mass immunization campaign to reach 72 million children, capitalizing on gains made this year. A total of some 290 000 vaccinators have been mobilized to go door-to-door to deliver two drops of oral polio vaccine (OPV) to every child under five in areas considered at "highest risk" of polio transmission.

26 Oct 2010

IDC grants MedImmune global rights to GLA adjuvant

Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC’s proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.

26 Oct 2010

Viral microRNA allows EBV to hide within cells and evade immune system

While most commonly associated with mononucleosis, Epstein-Barr virus (EBV) has been linked to many diseases that affect people long after the initial infection takes place, including some forms of cancer. In the current issue of the Journal of Biological Chemistry, scientists at The Wistar Institute describe how viral microRNA - small segments of RNA that suppress the effects of gene activity - allows EBV to hide within cells and evade the immune system.

26 Oct 2010

Salk discovers potential new target for MS

Scientists are closer to solving one of the many mysteries of multiple sclerosis and other demyelinating diseases, thanks to a recent study conducted at the Salk Institute for Biological Studies. The research revealed a previously unknown connection between two ion channels, which, when misaligned, can cause the many bizarre symptoms that characterize the condition.

26 Oct 2010

In India, major reduction seen in polio since 2009, WHO says on World Polio Day

There has been a significant reduction in the number of polio cases diagnosed in India this year compared with the same time last year, the WHO said on World Polio Day Sunday, IANS/Sify News reports.

26 Oct 2010

LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company developing innovative vaccine products, today announced positive results from a Phase I/II challenge study of its norovirus virus-like particle (VLP) vaccine candidate.

26 Oct 2010

Sanofi Pasteur presents Fluzone quadrivalent Phase II trial data for influenza at IDSA Annual Meeting

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today the results of a clinical trial of its investigational Fluzone Quadrivalent (Influenza Virus Vaccine) compared to the currently licensed Fluzone (Influenza Virus Vaccine). Data from the Phase II trial assessing the immunogenicity and safety of the investigational quadrivalent vaccine were presented at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia.

26 Oct 2010

CBER's Laboratory Quality System program receives accreditation

The U.S. Food and Drug Administration today announced that the American Association for Laboratory Accreditation has accredited the Laboratory Quality System program in the Center for Biologics and Evaluation Research (CBER) under ISO/IEC 17025 in the fields of biological and chemical testing.

26 Oct 2010

S.A.N.E. Vax requests temporary suspension of Gardasil sales as cervical cancer preventive

In a letter addressed to Dr. Margaret Hamburg, the FDA commissioner, Ms. Norma Erickson, president of S.A.N.E. Vax, Inc. stated her research team has revealed the fact that in November 2001 the VRBPAC (Vaccines and Related Biological Products Advisory Committee) mistakenly allowed the vaccine manufacturer to use "CIN 2/3, AIS, or cervical cancer; i.e. CIN 2/3 or worse by histology- with virology to determine the associated HPV type- as the primary endpoint in the evaluation of a vaccine to prevent cervical cancer."

25 Oct 2010

Vaccine News and Research

Latest Vaccine News and Research

Polio vaccination campaign targeting 72M children in 15 African countries announced; Ugandan health authorities declare polio outbreak

New findings suggest way to treat lung diseases

Flu deaths analyzed for future lessons

Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Scripps Florida scientist receives grant from Landenberger Foundation for HIV research

B.C. pharmacists are authorized to administer flu shots

USAID announces LAUNCH: Health innovators

Older adults with severe sepsis at higher risk for cognitive impairment

Bivalent oral polio vaccine produces better immune response than more commonly used trivalent vaccine, study says

PPD and VirtualScopics partner to provide medical imaging services

72 million children to be immunized against polio across 15 African countries

IDC grants MedImmune global rights to GLA adjuvant

Viral microRNA allows EBV to hide within cells and evade immune system

Salk discovers potential new target for MS

In India, major reduction seen in polio since 2009, WHO says on World Polio Day

LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting

Sanofi Pasteur presents Fluzone quadrivalent Phase II trial data for influenza at IDSA Annual Meeting

CBER's Laboratory Quality System program receives accreditation

S.A.N.E. Vax requests temporary suspension of Gardasil sales as cervical cancer preventive

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Vaccine News and Research

Latest Vaccine News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in